FIELD: biotechnology.
SUBSTANCE: disclosed are antibodies which specifically bind human CD38, pharmaceutical compositions and standard dosage forms containing said antibodies, as well as methods for preparing them. Also disclosed are methods of using antibodies to treat a disease associated with cells expressing CD38, for example, cancer.
EFFECT: invention provides more effective destruction of cells which express CD38, and more effective clinical response.
26 cl, 2 dwg, 19 tbl
Title | Year | Author | Number |
---|---|---|---|
PARVOVIRUS ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2020 |
|
RU2830441C2 |
COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA, AND COMPOSITIONS THEREOF, COMBINATIONS AND METHODS OF USING | 2015 |
|
RU2720282C1 |
ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE | 2016 |
|
RU2815681C1 |
METHODS OF COMBINED TREATMENT OF MALIGNANT NEOPLASMS, INCLUDING AGENTS BLOCKING CTLA-4 AND PD-1 | 2020 |
|
RU2833523C2 |
ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
ANTI-SIRPα ANTIBODIES | 2018 |
|
RU2771174C2 |
Authors
Dates
2024-09-19—Published
2020-04-23—Filed